Insmed Incorporated

Insmed is a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases. The company focuses on developing and commercializing first- and best-in-class therapies, with a primary emphasis on pulmonary and inflammatory conditions, including rare respiratory diseases. Insmed has transitioned into a commercial-stage company with a growing portfolio, including ARIKAYCE (amikacin liposome inhalation suspension) for refractory Mycobacterium avium complex (MAC) lung disease and BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis. The company maintains a robust pipeline of mid- to late-stage investigational medicines and early-stage research programs, including gene therapy and AI-driven protein engineering.